Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

Overview

This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.

Full Title of Study: “PARABO – Pain Evaluation in Radium-223 (Xofigo®) Treated mCRPC Patients With Bone Metastases – a Non-interventional Study in Nuclear Medicine Centers”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 20, 2020

Interventions

  • Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)
    • Dosage and treatment duration according to the decision of the treating physician

Arms, Groups and Cohorts

  • Radium-223 dichloride
    • Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.

Clinical Trial Outcome Measures

Primary Measures

  • Pain response
    • Time Frame: Up to 6 months
    • Determined by the worst pain item on the Brief Pain Inventory – Short Form (BPI-SF) patient questionnaire. A clinically meaningful pain response is defined as an improvement of two points from the baseline BPI-SF worst pain score at any post-baseline assessment.

Secondary Measures

  • Change of pain over time
    • Time Frame: Up to 6 months from baseline
    • Determined by evaluating the worst pain item as well as the subscale scores for pain severity and pain interference as determined by patient responses on the BPI-SF questionnaire.
  • Change in bone pain related quality of life
    • Time Frame: Up to 6 months from baseline
    • As determined by patient responses on the bone pain specific Functional Assessment of Cancer Therapy Quality of Life Measurement in patients with bone pain (FACT-BP) questionnaire
  • Pain control rate
    • Time Frame: Up to 6 months
    • As determined by the worst pain item on the BPI-SF patient questionnaire. Pain control is defined as no increase by two points from the baseline BPI-SF worst pain score.
  • Pain progression rate
    • Time Frame: Up to 6 months
    • As determined by the worst pain item on the BPI-SF patient questionnaire. Pain progression is defined as an increase by two points from the baseline BPI-SF worst pain score at any post baseline assessment.
  • Time to first pain progression
    • Time Frame: Up to 6 months
    • Defined as the time between the first injection of Radium-223 until an increase in the BPI-SF worst pain item by at least two points
  • Time to first opioid use
    • Time Frame: Up to 5.5 years
  • Summary description of covariates on pain response
    • Time Frame: Up to 6 months
    • The following covariates will be analyzed: opioid use, assessment of extent of bone metastases, location of bone metastases,level of alkaline phosphatase at baseline, PSA (Prostate Specific Antigen) level at baseline, WHO pain score at baseline, pretreatment with chemotherapy (yes/no), pretreatment with deep androgen ablation by treatment with abiraterone or enzalutamide (yes/no), extent of bone uptake in known lesions, BSI
  • Relation between bone uptake in known lesions and pain palliation
    • Time Frame: Up to 6 months
    • Only in patients with bone scan prior to start of treatment and a second scan during or within 6 weeks after end of Radium-223 treatment
  • Dosage of Radium-223
    • Time Frame: Up to 5 months
  • Number of injections of Radium-223
    • Time Frame: Up to 5 months
  • Course of blood count presented as percentage of patients below limit for further injections according to the local product information
    • Time Frame: Up to 5 months
  • Number of participants with Treatment-emergent Adverse Events (TEAE)
    • Time Frame: Up to 6 months
  • Time to next tumor treatment(s) (TTNT)
    • Time Frame: Up to 5.5 years
    • Defined as the time from the first application of Radium-223 until start of next mCRPC treatment including e.g. chemotherapy and/or hormonal treatment
  • Time to first symptomatic skeletal event (SSE)
    • Time Frame: Up to 5.5 years
    • Defined as the time between the first injection of Radium-223 until the occurrence of first SSE defined as the first use of external beam radiation therapy to relieve skeletal symptoms, new symptomatic pathological vertebral or non-vertebral bone fractures, spinal cord compression, or tumor-related orthopedic surgical intervention
  • Overall survival
    • Time Frame: Up to 5.5 years
    • Defined as the time interval from the start of Radium-223 therapy to death, due to any cause. Patients alive at the end of the study will be censored at the last date known to be alive.
  • Bone Scan Index (BSI) as Imaging Biomarker in metastatic castration-resistant prostate cancer (mCRPC)
    • Time Frame: Up to 6 months
    • Evaluated by comparing BSI values before and after Radium-223 treatment as well as by investigating the association of BSI with other outcome parameters like OS
  • Effect of concomitant drug treatment on pain, quality of life, and overall survival
    • Time Frame: Up to 5.5 years
    • Exploration of the influence of abiraterone, enzalutamide, opioids and denosumab on OS by number of injections (5-6 vs. 1-4)
  • Time from castration resistance to treatment with Radium-223
    • Time Frame: First treatment
    • Time from verified castration resistance to first injection of Radium-223
  • Description of covariates on duration of therapy
    • Time Frame: Up to 6 months
    • Description of covariates on duration of therapy (to get ≥ 5 injections versus ≤ 4 injections) of mCRPC patients during treatment with Radium-223.
  • Factors positively influencing mCRPC patients to get ≥ 5 injections versus ≤ 4 injections
    • Time Frame: Up to 6 months
    • (e.g. concomitant use of antihormonal therapy, no pre-treatment of chemotherapy)
  • Incidence of pathological fractures, non-pathological fractures and bone associated events during treatment and follow up
    • Time Frame: Up to 5.5 years

Participating in This Clinical Trial

Inclusion Criteria

  • Adult male patients diagnosed with CRPC with symptomatic bone metastases without known visceral metastases – Decision to initiate treatment with Radium-223 was made as per investigator's routine treatment practice Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice or participating in another observational study with Xofigo

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.